205 related articles for article (PubMed ID: 31538593)
1. Increased Risk for New-Onset Psychiatric Adverse Events in Patients With Newly Diagnosed Primary Restless Legs Syndrome Who Initiate Treatment With Dopamine Agonists: A Large-Scale Retrospective Claims Matched-Cohort Analysis.
Hankin C; Lee D; Garcia-Borreguero D; Wang Z
J Clin Sleep Med; 2019 Sep; 15(9):1225-1232. PubMed ID: 31538593
[TBL] [Abstract][Full Text] [Related]
2. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome.
Voon V; Schoerling A; Wenzel S; Ekanayake V; Reiff J; Trenkwalder C; Sixel-Döring F
BMC Neurol; 2011 Sep; 11():117. PubMed ID: 21955669
[TBL] [Abstract][Full Text] [Related]
3. Iron for the treatment of restless legs syndrome.
Trotti LM; Becker LA
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD007834. PubMed ID: 30609006
[TBL] [Abstract][Full Text] [Related]
4. Psychiatric comorbidity in children and adolescents with restless legs syndrome: a retrospective study.
Pullen SJ; Wall CA; Angstman ER; Munitz GE; Kotagal S
J Clin Sleep Med; 2011 Dec; 7(6):587-96. PubMed ID: 22171196
[TBL] [Abstract][Full Text] [Related]
5. Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome.
Bayard S; Langenier MC; Dauvilliers Y
Sleep; 2013 Oct; 36(10):1501-7. PubMed ID: 24082309
[TBL] [Abstract][Full Text] [Related]
6. Compulsive habits in restless legs syndrome patients under dopaminergic treatment.
Pourcher E; Rémillard S; Cohen H
J Neurol Sci; 2010 Mar; 290(1-2):52-6. PubMed ID: 19969309
[TBL] [Abstract][Full Text] [Related]
7. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
Bogan RK
Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
[TBL] [Abstract][Full Text] [Related]
8. Incident mental health episodes after initiation of gabapentinoids vs. dopamine agonists for early-onset idiopathic restless legs syndrome.
Costales B; Vouri SM; Brown JD; Setlow B; Goodin AJ
Psychiatry Res; 2023 Oct; 328():115479. PubMed ID: 37708806
[TBL] [Abstract][Full Text] [Related]
9. Targeted Pressure on Abductor Hallucis and Flexor Hallucis Brevis Muscles to Manage Moderate to Severe Primary Restless Legs Syndrome.
Kuhn PJ; Olson DJ; Sullivan JP
J Am Osteopath Assoc; 2016 Jul; 116(7):440-50. PubMed ID: 27367949
[TBL] [Abstract][Full Text] [Related]
10. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.
Trenkwalder C; Beneš H; Grote L; García-Borreguero D; Högl B; Hopp M; Bosse B; Oksche A; Reimer K; Winkelmann J; Allen RP; Kohnen R;
Lancet Neurol; 2013 Dec; 12(12):1141-50. PubMed ID: 24140442
[TBL] [Abstract][Full Text] [Related]
11. Health care resource utilization and costs associated with restless legs syndrome among managed care enrollees treated with dopamine agonists.
Meyers J; Candrilli S; Allen R; Manjunath R; Calloway M
Manag Care; 2012 Oct; 21(10):44-51. PubMed ID: 23156076
[TBL] [Abstract][Full Text] [Related]
12. High national rates of high-dose dopamine agonist prescribing for restless legs syndrome.
Winkelman JW
Sleep; 2022 Feb; 45(2):. PubMed ID: 34417810
[TBL] [Abstract][Full Text] [Related]
13. Dopamine agonists for restless legs syndrome.
Scholz H; Trenkwalder C; Kohnen R; Riemann D; Kriston L; Hornyak M
Cochrane Database Syst Rev; 2011 Mar; 2011(3):CD006009. PubMed ID: 21412893
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of restless legs syndrome with dopamine agonists.
Ondo W; Romanyshyn J; Vuong KD; Lai D
Arch Neurol; 2004 Sep; 61(9):1393-7. PubMed ID: 15364685
[TBL] [Abstract][Full Text] [Related]
15. A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation.
Winkelman JW; Mackie SE; Mei LA; Platt S; Schoerning L
Sleep Med; 2016 Aug; 24():18-23. PubMed ID: 27810181
[TBL] [Abstract][Full Text] [Related]
16. The psychopharmacological management of RLS in psychiatric conditions: a review of the literature.
Cuellar NG
J Am Psychiatr Nurses Assoc; 2012; 18(4):214-25. PubMed ID: 22529225
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR).
Oertel WH; Benes H; Bodenschatz R; Peglau I; Warmuth R; Happe S; Geisler P; Cassel W; Leroux M; Kohnen R; Stiasny-Kolster K
Neurology; 2006 Sep; 67(6):1040-6. PubMed ID: 16931508
[TBL] [Abstract][Full Text] [Related]
18. Relation of the International Restless Legs Syndrome Study Group rating scale with the Clinical Global Impression severity scale, the restless legs syndrome 6-item questionnaire, and the restless legs syndrome-quality of life questionnaire.
Allen R; Oertel W; Walters A; Benes H; Schollmayer E; Grieger F; Moran K; Kohnen R
Sleep Med; 2013 Dec; 14(12):1375-80. PubMed ID: 24246378
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.
García-Borreguero D; Allen RP; Kohnen R; Högl B; Trenkwalder C; Oertel W; Hening WA; Paulus W; Rye D; Walters A; Winkelmann J; Earley CJ;
Sleep Med; 2007 Aug; 8(5):520-30. PubMed ID: 17544323
[TBL] [Abstract][Full Text] [Related]
20. Risk of Cardiovascular Disease Associated with a Restless Legs Syndrome Diagnosis in a Retrospective Cohort Study from Kaiser Permanente Northern California.
Van Den Eeden SK; Albers KB; Davidson JE; Kushida CA; Leimpeter AD; Nelson LM; Popat R; Tanner CM; Bibeau K; Quesenberry CP
Sleep; 2015 Jul; 38(7):1009-15. PubMed ID: 26083613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
